Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

Cancer Science

Volumn 105, Issue 10, 2014, Pages 1321-1326

  Okusaka, Takuji ^a   Ikeda, Masafumi ^b   Fukutomi, Akira ^c   Ioka, Tatsuya ^d   Furuse, Junji ^e   Ohkawa, Shinichi ^f   Isayama, Hiroyuki ^g   Boku, Narikazu ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c Shizuoka Medical Centre   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; FOLFIRINOX; Irinotecan; Oxaliplatin; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ADULT; AGED; CLINICAL TRIAL; FEMALE; GENETICS; HUMAN; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PANCREATIC NEOPLASMS; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 84911041867     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12501     Document Type: Article

References (17)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Japanese Ministry of Health, Labour and Welfare. Statistical investigation result. 2012: [cited 27 November 2013] Available from URL: http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/index.html [In Japanese]
3. Center for Cancer control and Information Services, Latest Cancer Statistics. [cited 21 November 2013] Available from URL: http://ganjoho.jp/public/statistics/pub/statistics01.html [In Japanese]
4. Burris HA III, Moore MJ, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
5. Moore MJ, Goldstein D, Hamm J et al. Erlotnib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer instutite of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
6. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreas cancer. N Engl J Med 2011; 364: 1817-25.
7. Ueno H, Okusaka T, Funakoshi A et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007; 59: 447-54.
8. Okusaka T, Funakoshi A, Furuse J et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008; 61: 615-21.
9. Kindler HL, Ioka T, Richel DJ et al. Axitnib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomized phase 3 study. Lancet Oncol 2011; 12: 256-62.
10. Ueno H, Ioka T, Ikeda M et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-8.
11. Ando Y, Saka H, Ando M et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6.
12. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-8.
13. Marcuello E, Altes A, Menoyo A et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-82.
14. Von Hoff DD, Ervin T, Arena PF et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.
15. Mahaseth H, Brutcher E, Kauh J et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas 2013; 42: 1311-5.
16. Oikonomopoulos GM, Syrigos KN, Skoura E, Saif MW. FOLFIRINOX: from the ACCORD study to 2014. JOP 2014; 15: 103-5.
17. Sharma M, Catenacci DV, Karrison T et al. A UGT1A1 genotype guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies. J Clin Oncol 2014; 32(Suppl): 4125.